Dukes Iain D.
Dukes Iain D.'s purchase track record
Dukes Iain D. has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 2/20/2024 | IOVA | $293K | -14.2% | -6.2% | +12.5% |
| 11/23/2022 | IOVA | $61K | +19.0% | +29.7% | +2.2% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
Iovance Biotherapeutics sees analyst target raise and whale activity. Recent reports show large investors were active in IOVA shares, indicating heightened interest. Baird kept a neutral stance but lifted its price target to $11, above its prior level. The Q2 2026 earnings call highlighted ongoing clinical progress, which aligns with the analyst’s revised outlook. The stock is near the upper end of its 52‑week range.
Transaction History
| TRAW | ▲ Buy | Grant | 36,943 | $0 | 12/12/2025 | View on chart |
| TRAW | ▲ Buy | Grant | 67,550 | — | 4/1/2024 | View on chart |
| TRAW | ▲ Buy | Grant | 1,645,100 | — | 4/1/2024 | View on chart |
| TRAW | ▲ Buy | Grant | 66,687 | — | 4/1/2024 | View on chart |
| IOVA | ▲ Buy | Open Market | 32,000 | $293K | 2/20/2024 | View on chart |
| IOVA | ▲ Buy | Open Market | 10,000 | $61K | 11/23/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 2, 2026
Traws Pharma listed in Benzinga health care movers
Traws Pharma was included in Benzinga's recent lists of health care stocks moving in pre-market and after-market sessions. These mentions indicate that the stock experienced price volatility relative to its peers during those trading periods. The company's shares currently trade near the middle of their 52-week range, with an average analyst target of $1.00.
Traws Pharma listed in Benzinga health care movers. Traws Pharma was included in Benzinga's recent lists of health care stocks moving in pre-market and after-market sessions. These mentions indicate that the stock experienced price volatility relative to its peers during those trading periods. The company's shares currently trade near the middle of their 52-week range, with an average analyst target of $1.00.